Immediate Impact
2 by Nobel laureates 3 from Science/Nature 57 standout
Citing Papers
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial
2024 Standout
Towards targeting the breast cancer immune microenvironment
2024 Standout
Works of Smita Asare being referenced
Abstract P3-10-06: Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ˜1000 patients across 10 therapies
2019
Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Smita Asare | 179 | 95 | 14 | 73 | 22 | 293 | |
| Deirdre Kelly | 156 | 100 | 11 | 83 | 28 | 333 | |
| Craig Vargo | 169 | 75 | 37 | 23 | 20 | 333 | |
| Shaohan Wu | 95 | 106 | 2 | 16 | 20 | 309 | |
| Anna Petit | 94 | 151 | 29 | 20 | 20 | 312 | |
| Xin Wang | 52 | 36 | 9 | 36 | 19 | 249 | |
| Ephraim Tang | 215 | 31 | 8 | 107 | 18 | 307 | |
| Leting Zheng | 102 | 53 | 8 | 140 | 17 | 300 | |
| S. Mariucci | 196 | 81 | 7 | 103 | 18 | 332 | |
| Sara Hafezi‐Bakhtiari | 131 | 31 | 10 | 11 | 24 | 258 | |
| Miguel Méndez | 166 | 50 | 2 | 19 | 29 | 239 |
All Works
Login with ORCID to disown or claim papers
Loading papers...